The Forum focuses on inspiring participants about innovations that can lead dermatology in its next generation of important products and services. By including physicians, researchers, inventors, investors, strategic corporate partners, service providers, government regulators, patient advocates, and other stakeholders, the Forum is a unique networking venue where leaders can communicate with, learn from, and collaborate with each other on the future of dermatology innovation.
Michael D. Abramoff, MD, PhD, Fellow, IEEE, is a neuroscientist, computer engineer and fellowship-trained retina specialist. He is founder and executive chairman of Digital Diagnostics, Inc., the first company ever to receive FDA clearance for an autonomous AI diagnostic system. As the Watzke Professor of Ophthalmology at the University of Iowa, he has authored over 300 peer-reviewed publications, inventor on 17 issued patents, and has been cited over 35,000 times. As expert on AI in healthcare, and AI ethics, he has briefed the US Congress, the White House, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC), and chairs the Foundational Principles of Ophthalmic Imaging Algorithmic Interpretation workgroup, originally instituted by FDA.
In 2010, Dr. Abramoff's research findings led him to found Digital Diagnostics to bring patients more affordable, more accessible, and higher quality healthcare.
Digital Diagnostics is a leading AI diagnostics company on a mission to transform the affordability, quality, and accessibility of healthcare. The company is focused on developing clinically aligned autonomous AI systems. By enabling diagnostic assessment in primary care settings, Digital Diagnostics aims to increase patient access to high-quality, affordable disease detection.
Dr. Breslin is Director of Operations & Partnerships for Advancing Innovation in Dermatology (AID) where she is responsible for building relationships among diverse stakeholders and implementing program initiatives across AID's platform. Trained as a virologist, she began her career at PTC Therapeutics, Inc. initially as part of the antiviral research team discovering small molecules for the treatment of HIV and Hepatitis C, and subsequently within corporate development. Within corporate development she helped build the Alliance Management function and as Director of Business Development was responsible for licensing and technology partnering campaigns in oncology, infectious diseases, and genetic disorders, and supported private and public financing events.
Dr. Breslin received her B.S. in Molecular Biology from Florida Institute of Technology, her Ph.D. in virology from North Carolina State University, and studied as a post-doctoral fellow at the University of Colorado Health Sciences Center.
Dr. Char is an Assistant Professor in the Department of Anesthesia, Perioperative and Pain Medicine at the Stanford University School of Medicine and a Pediatric Cardiac Anesthesiologist at Lucile Packard Children’s Hospital. His research focuses on ethical issues arising in the care of critically ill neonates, infants and children, particularly children with congenital cardiac disease.
Edward Hsia, PhD is currently VP, External Research & Innovation, at Almirall where he leads the identification and evaluation of early stage external innovation opportunities. Dr. Hsia is responsible for developing a network within academia, research institutions, biotech/pharma companies, and start-up firms that will ultimately help strengthen Almirall's early stage pipeline. Dr. Hsia has been in the dermatology field since 2004. Beginning with Connetics and through acquisitions by Stiefel and GSK, Dr. Hsia gained increasing responsibilities in the areas of research and early development. Just prior to joining Almirall in 2017, Dr. Hsia was Executive Director at Allergan where he led the research effort in medical dermatology. Dr. Hsia holds a B.S. in Biological Sciences from UC Davis, and a PhD in Biochemistry from Boston University.
Dr. Kaplan is a Professor of Dermatology and Immunology at the University of Pittsburgh. His research is dedicated to understanding the mechanisms that underlie skin immunity and the interplay of different immune cells types that reside in the skin. Recently, his lab has focused on the contribution of non-hematopoetic cells to skin immunity to better understand the mechanisms driving immune-mediated skin diseases in an effort to prevent its onset and devise novel therapeutics. Dr. Kaplan received his BS from Yale University, his MD/PhD from Washington University in St. Louis, and he did his residency/fellowship training at Yale University in the Department of Dermatology.
Dr. Kim is Co-Director for the Center for the Study of Itch and Sensory Disorders (CSISD) and Associate Professor of Medicine at Washington University School of Medicine in St. Louis. Key discoveries from his laboratory include the first identification of group 2 innate lymphoid cells (ILC2s) in the skin of both mice and humans and their role in the pathogenesis of atopic dermatitis (AD) or eczema. Most recently, he has discovered how the immune system directly regulates sensory neurons to modulate the sensation of itch and how natural killer (NK) cells may be used as an immunotherapy strategy for AD. These studies have revealed novel therapeutic strategies which have led to successful clinical trials for new drugs for AD. He has multiple patents pending that led to the formation of Nuogen Pharma, Inc. that is developing JAK inhibitors for chronic pruritus. Dr. Kim’s research on innate immunity and neuroimmune regulation of AD and itch has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and the International League of Dermatology Societies.
Dr. Ko is Chief of Medical Dermatology at Stanford and spearheads the dermatology department's efforts around digital health, quality and value-based care. He is active in a number of leadership roles within Stanford Medicine including chairing the Clinic Advisory Council, a forum of medical and executive leaders of Ambulatory care and as a Medical Director of Patient Experience. His passion for innovating on models of care delivery drives his efforts and research around layering advances in artificial intelligence on remote care capabilities to enhance access, quality and value of dermatologic care. He leads the American Academy of Dermatology task force on Augmented Intelligence.
Dr. Köhl is Professor of Immunology and the founding Director of the Institute for Systemic Inflammation Research at the University of Lübeck. He obtained his medical degree at the University of Mainz and studied as a postdoc at the Institute for Medical Microbiology at the Medical School Hannover (MHH). His research focuses on the innate immune system, in particular the inflammatory and regulatory roles of the anaphylatoxins and their cognate receptors in allergic, autoimmune and infectious diseases. Dr. Köhl has published more than 150 original articles and reviews in international peer-reviewed journals.
Dr. Yuan Liu is a software engineer on the dermatology team in Google Health. She currently leads various dermatology related research and development efforts, with a focus on building AI assistant tools to improve the world's access to accurate information and care for everyone. She also worked on applying computer vision techniques to large-scale user generated content in Google Maps. Prior to joining Google, she obtained her PhD in medical image processing at Vanderbilt University, where she conducted intelligent analysis of radiology images (CT, MRI) to advance image-guided neurosurgical procedures. She currently serves as a co-chair for the upcoming ISIC Skin Image Analysis workshop at CVPR, and guest editor for Medical Image Analysis Journal.
Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology. He serves as the Vice Chair for Clinical Trials, the Director of the Clinical Unit for Research Innovation and Trials (CUReIT), Director of the Center for Skin and Related Musculoskeletal Diseases and the Associate Program Director for the Harvard Combined Internal Medicine-Dermatology Residency Training Program at Brigham and Women’s Hospital in Boston. Dr. Merola earned his medical degree at New York University School of Medicine in New York, New York, followed by his Master of Medical Sciences degree at Harvard Medical School. He completed an internship in Internal Medicine at the Hospital of the University of Pennsylvania in Philadelphia, followed by a residency in Dermatology at New York University Medical Center. He continued with a residency in Internal Medicine and a fellowship in Rheumatology at Brigham and Women’s Hospital.
Dr. Merola is on the Scientific Board of the National Psoriasis Foundation (former Medical Board Member), the Board of the International Dermatology Outcome Measures Group and Executive Committee for GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), the Board of the Lupus Foundation of America and is on the Board and Founding President of the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN). He is also the president-elect of the Medical Dermatology Society. He is a councilor for the International Eczema Council as well as the International Psoriasis Council.
Lloyd S. Miller, M.D., Ph.D., joined Janssen Immunology in January 2020 as Vice President, Immunodermatology Disease Area Stronghold (DAS) Leader. In this role, Dr. Miller's primary objective is to drive the scientific leadership in dermatology and set the strategy to meet the needs of millions of patients living with immune-mediated skin diseases who have inadequate available treatments. In this role, he serves as a member of the Janssen Immunology Core Leadership Team and Immunology Portfolio Committee and is based in Spring House, Pennsylvania.
Dr. Miller earned his B.A. in biology at Johns Hopkins University and received his M.D. and Ph.D. degrees from the State University of New York Downstate Medical Center in Brooklyn. His dermatology residency and post-doctoral research fellowship were completed in the Specialty Training and Advanced Research (STAR) program at the University of California Los Angeles (UCLA). At UCLA, he started his basic science and translational research program that involved the study of skin infections and inflammation, the skin microbiome and wound healing responses. In 2012, Dr. Miller moved his research program to the Johns Hopkins Department of Dermatology, where he served as Vice Chair for Research in Dermatology and Professor of Dermatology, Infectious Diseases, Orthopedic Surgery and Materials Science and Engineering at the Johns Hopkins University School of Medicine. Over the years, Dr. Miller has published more than 100 peer-reviewed manuscripts, review articles, book chapters and editorials and has given over 75 oral presentations at national and international scientific programs and meetings. In addition, he has received several NIH grants, in addition to private foundation and industry funding awards for his research. Throughout his career, he practiced both general dermatology and specialized wound Care.
Dr. Miller also served as a standing roster member on the Arthritis, Connective Tissue and Skin (ACTS) NIH study section, the Medical and Scientific Review Committee for the Dermatology Foundation, the Scientific Program Committee for the Society for Investigative Dermatology and was elected to the American Society of Clinical Investigation. He is certified by the American Board of Dermatology.
Dr. Arash Mostaghimi received his medical degree from Harvard Medical School in 2007 as well as a Masters in Public Administration from the Harvard Kennedy School. He completed his residency in Internal Medicine and Dermatology at Beth Israel Deaconess Medical Center. Dr. Mostaghimi joined the faculty in the Department of Dermatology at Brigham and Women's Hospital in 2013. He received a Masters in Public Health in Clinical Effectiveness at the Harvard T.H. Chan School of Public Health in 2015.
Dr. Mostaghimi is an assistant professor of dermatology, director of the inpatient dermatology consult service, and co-director of the Complex Medical Dermatology Fellowship at Brigham & Women’s Hospital. His research focuses on understanding variations in dermatologic care and improving care delivery to optimize resource utilization, encourage patient autonomy, and reduce disparities. His specific interests include (1) reducing unnecessary diagnostic testing and drug monitoring within dermatology, (2) understanding the interface between dermatology and other medical specialties, (3) determining best practices for the treatment of orphan dermatologic conditions, and (4) characterizing dermatologic practice patterns, utilization, and costs. Dr. Mostaghimi's daughter has alopecia areata; and a portion of his research is focused on understanding the epidemiology and clinical impact of this disease. In addition, he is involved in clinical trials focused on bringing innovative therapies for alopecia areata to patients who need them the most.
Dr. Mostaghimi also has a podcast with Dr. Kristina Liu called Topical, which can be heard at www.topicalpod.com.
Dr. Oyesiku is the team leader of the 2021 first place Hacking Dermatology team, Folliculology. Folliculology aims to address access, educate, and build networks between barbers and dermatologists to improve the quality of life of those with follicular disorders through expert advice, recommendations and direct care. The app helps barbers and individuals: Find curated resources and dermatologists; Form a plan of care; and Follow recommendations from experts. Dr. Oyesiku is a recent graduate from the University of Miami Miller School of Medicine with a Masters of Public Health from Boston University and BA in Anthropology from Emory University. She will be an intern at Holy Cross Hospital in Florida and a dermatology resident at the University of Washington starting in July 2022. As a medical student, she was a global health dermatology research fellow under the mentorship of Dr. Esther Freeman at Massachusetts General Hospital. She is a co-founder, webmaster, creative content and social media director of the International Alliance for Global Health Dermatology (GLODERM). Her research has spanned various areas in public health and medicine primarily examining issues related to access to care, diagnostic delays, diffusion of innovations and medical anthropology. Prior to medical school, she was a Peace Corps Health Volunteer in rural Mozambique and completed a post baccalaureate program at Agnes Scott College.
Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline’s Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 30 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.
Dr. Sokol is a practicing allergist and principal investigator at MGH, where her laboratory studies the cutaneous neuro-immune interactions promoting allergic immune disease and underlying allergen induced itch responses. She performed her PhD with Dr. Ruslan Medzhitov at Yale University followed by her clinical training at Massachusetts General Hospital and postdoctoral training in the laboratory of Dr. Andrew Luster. She has provided several seminal contributions to the field, establishing the cysteine protease activity of allergens as Type-2 adjuvants, illustrating a role for basophils in the skewing of Th2 cells, and identifying a requirement for CCR8 in the entry of Th2-skewing dendritic cells into the lymph node. Most recently her laboratory established sensory neurons as crucial in linking allergen detection with dendritic cell activation and the initiation of the allergic immune response through interactions between Substance P and MRGPRA1. In addition to these roles, Dr. Sokol is the Associate Program Director for the Physician-Scientist Pathway in the Internal Medicine Residency at MGH.
Dr. Ulrich H. von Andrian, "Uli", received his medical degree from the Ludwig-Maximilians University in Munich, Germany, where he also conducted doctorate research on blood-brain barrier dysfunction following brain injury. In 1989, he joined the La Jolla Institute for Experimental Medicine and UCSD as a postdoctoral fellow working with Dr. Karl-E. Arfors. His postdoctoral research involved the development of intravital microscopy techniques that led to the discovery of the multi-step leukocyte adhesion cascade in vivo. After a second postdoctoral fellowship in the laboratory of Dr. Eugene C. Butcher at Stanford University, Dr. von Andrian joined the Faculty of Harvard Medical School in 1994. He was appointed to his current position in 2006. His scientific research is focused on the regulation and function of immune cells in health and disease. To this end, his laboratory employs intravital microscopy techniques combined with other experimental approaches to study the migration, communication, differentiation and function of immune cells in living animals.
VeraDermics, Inc. is a preclinical stage, dermatology-focused pharmaceutical company. Dr. Waldman is a Dermatologist by training who completed his Residency at the University of Connecticut after graduating from the University of Missouri-Kansas City School of Medicine 6 Year Combined BA/MD Program. Dr. Waldman is an established researcher in dermatology having written more than 100 peer-reviewed articles, book chapters, abstracts, and posters. He is also the author of a dermatology textbook that aims to help primary care doctors diagnose and treat common skin diseases titled Dermatology for the Primary Care Provider. Dr. Waldman has been awarded numerous national accolades for his work including an Excellence in Patient Care award from the American Academy of Dermatology and Resident of Distinction Award from the DermMentors Foundation.
Dr. Werth earned her Medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She completed a Residency in Internal Medicine at Northwestern Memorial Hospital in Chicago, Illinois, and a Dermatology Residency and Immunodermatology Fellowship at New York University School of Medicine. She joined the faculty at the University of Pennsylvania in 1989 and has developed an internationally recognised programme in autoimmune skin diseases.
She is a co-founder of the Rheumatologic Dermatology Society and Past President of the group. She is co-founder of the Medical Dermatology Society, and a recipient of their lifetime achievement award. She initiated the combined internal medicine/dermatology residency programme in USA, which has successfully trained prominent leaders in complex medical dermatology.
She has a longstanding interest in clinical and translational research pertaining to cutaneous lupus erythematosus, with a focus on improving the treatment and outcomes. She has developed and validated disease severity tools now used in many international trials in lupus erythematosus, with a goal to advancing evidence for current and new therapeutics targeting these diseases. Her laboratory studies include studies of the mechanisms of cutaneous lupus, biomarker studies in cutaneous lupus examining the heterogeneity of the disease that relate to pathogenesis, and ultraviolet light effects on skin. Her work has been funded by the Dermatology Foundation, NIH, the VA, the DOD, numerous autoimmune disease foundations, and industry.
Francesca Domenech Wuttke, Ph.D. is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall. Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 25 years of clinical, research, commercial, strategic and transactional experience. She has worked with diverse organizations including start- ups, consulting, large and specialty pharma as well as academia. Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr. Wuttke led Almirall's Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organization as well as managing the strategy and commercialization for the existing portfolio of cell therapy assets. Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.
Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children's Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Cha is a Managing Partner of Frazier's Life Sciences team. He joined the firm in 2021 and has over 20 years of experience investing in public and private biopharmaceutical and medical device companies.
He was previously a Managing Partner at Vivo Capital. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND) and KalVista Pharmaceuticals (NASDAQ: KALV), and has previously served on the boards of Aclaris Therapeutics (NASDAQ; ACRS), Biohaven Pharmaceuticals (NYSE: BHVN), and many other private and public biopharmaceutical companies.
Dr. Cha is a co-founder of the annual Dermatology Summit and Dermatology Innovation Forum. He also worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.
Dr. Cha received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.
John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He had an active clinical practice for seventeen years and remains board certified in dermatology. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare.
Dr. Walker co-founded Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and has served as its President and CEO and a member of the board of directors since 2012. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption LLC, a biopharmaceutical assets management company, in 2012. He co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and continues to serve on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc. (NASDAQ: ALDX), a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received a Bachelor of Arts in biology from Lehigh University, a Master of Business Administration from The Wharton School, University of Pennsylvania, and a Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine.
Networking within the virtual meeting platform will be open to all attendees on the day of the event. Attendees can network via chat, video and message board.
Conference virtual platform login page
The current program agenda can be found here.
As an attendee you will be able to enjoy a unique, interactive experience from the comfort and convenience of your home or office. To make sure you are ready to go please review the following documents:
If you are interested in a sponsorship opportunity, please contact Erin Conner at firstname.lastname@example.org
Please contact email@example.com
Requests for registration fee cancellations for the conference must be received on or before June 11, 2021. At the discretion of the confrence organizers, a refund via the method of original payment, minus a $25 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on June 11, 2021. Written notice of your cancellation should be sent to firstname.lastname@example.org
No damages or refunds shall be due for a failure of performance or because of a delay or cancellation of one or more of the AID Initiatives by the occurrence of any contingency beyond the reasonable control of Host. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, strikes, labor disputes, picketing or work stoppage (actual or threatened), an epidemic, pandemic or disease, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, change in virtual meeting platform ownership or management company, technology updates to the virtual meeting platform, interruptions or failure of the Internet, accessibility, connectivity or network connections, or any other acts beyond the reasonable control of the responsible parties.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.